Editas Medicine, Inc.
About Editas Medicine, Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $40.5M
- Net income
- -$160.1M
- Total assets
- $186.5M
- Market cap
- $415.9M
- Operating margin
- -394.9%
- Net margin
- -395.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $40.5M
- Operating expenses
- $200.5M
- Operating income
- -$160.0M
- Income tax
- $0
- Net income
- -$160.1M
- EPS (basic)
- $-1.80
- EPS (diluted)
- $-1.80
Balance sheet
- Total assets
- $186.5M
- Current assets
- $163.9M
- Total liabilities
- $159.2M
- Current liabilities
- $46.2M
- Shareholders’ equity
- $27.3M
Cash flow
- Operating cash flow
- -$165.2M
- Investing cash flow
- $138.7M
- Financing cash flow
- $40.5M
- Net cash flow
- $13.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $415.9M
- EPS (diluted)
- $-1.8
- Shares outstanding
- 157.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 3, 2016
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $160.1M in FY2025.
- Revenue grew 59% from FY2021 to FY2025.
- Trading 36% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Editas Medicine, Inc..
Write a review
News about Editas Medicine, Inc.
News & sentiment via Polygon.io
